Treatment of malignant endocrine pancreatic tumors with a combination of α-interferon and somatostatin analogs
- 80 Downloads
Somatostatin analogs and α-interferon induce good responses as single drugs in the treatment of endocrine pancreatic tumors. We examined the efficacy and tolerability of the combination of α-interferon and somatostatin analogs in 16 patients with metastatic endocrine pancreatic tumors. All patients except one had received prior treatment and were in a progressive state. Doses of α-interferon and somatostatin analogs were individually titrated. The α-interferon doses varied between 9 and 25 million units per week and were combined with 100–1500 µg of octreotide or 6000 µg of lanreotide daily. Radiological response was seen in 3 of 16 (19%) patients (median duration 23 mo). Biochemical response was seen in 10 of 16 (62.5%) patients (median duration 22 mo). All three patients previously progressing on both α-interferon and somatostatin analog as single drugs achieved a stabilization of the disease when treated with the combination (median duration 10 mo). Seven of eight (88%) patients previously progressing on α-interferon treatment benefited from the combination with biochemical partial response or stabilization. All six patients previously progressing during somatostatin analog treatment achieved biochemical partial response or stabilization. More than 80% of patients who progressed during previous treatment with either drug benefited from the combined treatment, which also was well tolerated. Thus, a combination of α-interferon and somatostatin analogs may be considered for patients previously progressing on treatment with α-interferon or somatostatin analogs. However, in this study, the value of sequential treatment has not been evaluated.
Key Wordsα-Interferon biotherapy combination treatment endocrine pancreatic tumors somatostatin analogs
Unable to display preview. Download preview PDF.
- 1.Wilder, R.M., Allan, F.N., Power, M.H. and Robertson, H.E. (1927). Carcinoma of the islands of the pancreas: hyperinsulinism and hypoglucemia. JAMA 89:348–355.Google Scholar
- 6.Wellborn, R.B., Wood, S.M., Polak, J.M., et al. (1981). Pancreatic endocrine tumors, in Gut Hormones, 2nd ed. (S.R. Bloom, and J.R. Polak, eds.), pp547–554, Churchill Livingstone, London.Google Scholar
- 18.Westlin, J.E., et al. (1992). Scintigraphy using a 111-indiumlabeled somatostatin analogue for localization of neuroendocrine tumors. Antibody Immunoconj. Radiopharm. 5:367–384.Google Scholar
- 21.Arnold, R., et al. (1996). Somatostatin analogue and inhibition of tumor growth in metastatic endocrine gastroenteropancreatic tumors. Gut 38:403–408.Google Scholar